FIGURE 5.

League tables of pooled mixed comparison, which show the value of HR/OR with 95% CI between two random treatment agents (all groups were included, for example, “Network comparison of OS in nonselective PD‐L1 patients” meant the OS analysis in all patients without PD‐L1 section, so as others. * meant that only one survival index was accessed and included: OS or PFS. Durva* and Durva+Treme* were from MYSTIC, a three‐arm study; Nivo+Ipi* was from checkmate 227, a three‐arm study; Camre+Chemo was from Camel, an ongoing head‐to‐head study; Pembro* was from Keynote 024 and Keynote 042, both focusing on PD‐L1 positive NSCLC)